Table II. Summary of experimental uses for 100 randomly chosen mAbs from different commercial suppliers.

For seven major suppliers, 100 mAbs were randomly selected. The total percentage of mAbs from each supplier reported to be usable for each of the indicated applications is shown. IB, immunoblot; ICC/IHC, immunocytochemistry or immunohistochemistry; IP, immunoprecipitation; Multiple, useful in at least two of these applications; All, useful in all three applications. The names of the individual suppliers have been concealed for this analysis and match those in Table I.

mAbs by supplier	IB (%)	IHC/ICC (%)	IP (%)	Multiple (%)	All (%)
Supplier A	87	28	11	35	3
Supplier B	93	26	6	29	0
Supplier C	96	83	0	81	0
Supplier D	91	14	0	13	0
Supplier E	85	64	25	60	17
Supplier F	67	70	34	55	21
Supplier G	83	100	40	85	38
Overall mean	86	55	17	51	11
This study	56	90	66	74	42